Humanin Dosing: 0.5-2mg HNG Daily Protocol

Humanin is a 24-amino acid mitochondrial-derived peptide originally discovered in 2001 as a factor protecting neurons from Alzheimer's disease-related cell death. The potent analog HNG (S14G-humanin) is most commonly used. This is not medical advice.

Quick Reference: Community Protocol

Humanin is not in the standard cheat sheet — this is a community protocol based on animal research extrapolation and empirical reports. Native humanin is rarely used due to HNG's 1,000x greater potency.

For the full humanin peptide profile, vendor pricing, and research summaries, see our humanin peptide page.

Cycling Details

Start at 0.5 mg HNG daily during Week 1 to assess tolerance, then increase to 1-2 mg daily if well-tolerated. Most community users settle at 1 mg daily as their standard protocol.

The 8-12 week on / 4-8 week off cycling approach is conservative given the complete absence of human clinical trial data for exogenous supplementation. Natural humanin levels are constant (declining with age), so the cycling rationale is precautionary rather than evidence-based.

Routes of Administration

Subcutaneous (community standard): Abdomen, love handles, or thighs. Volume is typically 0.1-0.3 mL with insulin syringe. Once daily, morning.

Intravenous / Intracerebroventricular: Used in animal studies only. Not practical or recommended for community use.

Reconstitution Quick Reference

Math: 5,000 mcg / 2 mL = 2,500 mcg/mL. 1,000 mcg / 2,500 = 0.4 mL = 40 units. Swirl gently, refrigerate, use within 28 days.

For step-by-step reconstitution instructions, see the BPC-157 reconstitution guide — same technique applies to all lyophilized peptides.

Where These Numbers Come From

Humanin research is extensive in animal and cell models but completely lacks human clinical trials for exogenous supplementation.

Humanin was discovered by Hashimoto et al. through a functional screen of cDNA from an Alzheimer's disease patient's brain, identified as a factor that protected neurons from amyloid-beta toxicity (Hashimoto et al., 2001). A landmark study demonstrated that humanin overexpression extends lifespan in C. elegans through daf-16/FOXO-dependent mechanisms (Muzumdar et al., 2020).

Humanin directly prevents mitochondrial membrane permeabilization by inhibiting Bax and Bid oligomerization — a key step in the intrinsic apoptosis pathway (Bhatt et al., 2017). The analog HNG also improves insulin sensitivity and enhances glucose-stimulated insulin secretion (Kuliawat et al., 2013).

No human clinical trials exist for exogenous humanin/HNG supplementation. Dosing is entirely extrapolated from animal pharmacokinetic data, in vitro bioactive concentrations, the peptide's natural age-related decline, and community experience.

Stacking Protocols

Start each peptide individually to assess response. Use different injection sites when combining. Cancer screening should be up-to-date before using anti-apoptotic peptide stacks.

Side Effects & Safety

• Generally well-tolerated at 0.5-2 mg HNG daily in community reports
• Injection site reactions — standard mild redness, occasional irritation
• Mild fatigue — occasional, usually transient
• Anti-apoptotic concern — humanin's potent anti-apoptotic activity raises theoretical questions about cancer risk; avoid with active malignancy
• Metabolic effects — enhanced insulin sensitivity; monitor blood glucose if diabetic
• No serious adverse events reported in community forums or animal studies
• Pregnancy/lactation — no safety data; avoid

Frequently Asked Questions

What is the standard humanin dose?

There is no established clinical dose. Community protocols use HNG (S14G-humanin) at 0.5-2 mg subcutaneous daily, cycled 8-12 weeks on/off. All dosing is experimental and extrapolated from animal research.

What is the difference between humanin and HNG?

HNG (S14G-humanin) has a glycine substitution at position 14 that increases potency approximately 1,000-fold. Virtually all community use and most modern research uses HNG.

Is humanin safe?

Animal studies show excellent safety profiles. No human clinical trials exist. Community reports indicate good tolerability. The main theoretical concern is that potent anti-apoptotic effects could theoretically affect tumor suppression.

Can humanin be stacked with MOTS-c?

Yes — this is the most popular mitochondrial peptide stack. Both are mitochondrial-derived peptides with complementary mechanisms: humanin provides cytoprotection while MOTS-c targets metabolic regulation.

Why do humanin levels decline with age?

Humanin is encoded in mitochondrial DNA, and mitochondrial function declines with age. Lower humanin correlates with increased susceptibility to neurodegeneration and metabolic disease.

How long should a humanin cycle last?

8-12 weeks on, 4-8 weeks off. This conservative cycling approach accounts for the complete absence of long-term human safety data.

Related Guides

• Humanin Benefits: 5 Effects You Should Know — neuroprotection, cardiovascular, insulin sensitivity evidence
• Humanin peptide page — vendor pricing and full profile
• SS-31 Dosing Guide — mitochondrial-targeted peptide for stacking
• MOTS-c Dosing Guide — another mitochondrial-derived peptide
• GHK-Cu Dosing Guide — anti-aging copper peptide
• FOXO4-DRI Dosing Guide — senolytic peptide for longevity
• Peptide Stacking Guide — principles for combining longevity peptides
• Calculate Your Humanin Cycle Cost — estimate vials needed and total cost

References

For educational and research purposes only. This is not medical advice. Humanin/HNG supplementation is entirely experimental with no human clinical trials. Consult a healthcare provider before use.